Sage Journals: Discover world-class research

Abstract

Amyloid beta (Aβ) peptides are the major constituent of amyloid plaques, one of the hallmark pathologies of Alzheimer's disease. Accurate and precise quantitation of these peptides in biological fluids is a critical component of Alzheimer's disease research. The current most established assay for analysis of Aβ peptides in preclinical research is enzyme-linked immunosorbent assay (ELISA), which, although sensitive and of proven utility, is a multistep, labor-intensive assay that is difficult to automate completely. To overcome these limitations, the authors have developed and optimized simple, sensitive, homogeneous 384-well assays for Aβ1-42 and Aβ1-40 using AlphaScreen™ technology. The assays are capable of detecting Aβ peptides at concentrations <2 pg/mL and, using a final assay volume of 20 µL, routinely generate Z′ values >0.85. The AlphaScreen™ format has the following key advantages: substantially less hands-on time to run, easier to automate, higher throughput, and less expensive to run than the traditional ELISA. The results presented here show that AlphaScreen™ technology permits robust, efficient, and cost-effective quantitation of Aβ peptides. (Journal of Biomolecular Screening 2008:101-111)

Keywords

AlphaScreen™amyloid beta peptides Alzheimer's disease

References

Bentahir M. , Nyabi O. , Verhamme J. , Tolia A. , Horre K. , Wiltfang J. , et al: Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006;96:732-742.

Khorkova OE , Patel K. , Heroux J. , Sahasrabudhe S: Modulation of amyloid precursor protein processing by compounds with various mechanisms of action: detection by liquid phase electrochemiluminescent system. J Neurosci Methods 1998;82(2):159-166.

Best JD , Jay MT , Otu F. , Ma J. , Nadin A. , Ellis S. , et al: Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575. J Pharmacol Exp Ther 2005;313:902-908.

Clarke EE , Shearman MS : Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay. J Neurosci Methods 2000;102:61-68.

Vanderstichele H. , De Meyer G. , Andreasen N. , Kostanjevecki V. , Wallin A. , Olsson A. , et al: Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment . Clin Chem 2005 ;51:1650-1660.

Bard F. , Cannon C. , Barbour R. , Burke R-L. , Games D. , Grajeda H. , et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.

Cleary JP , Walsh DM , Hofmeister JJ , Shankar GM , Kuskowski MA , Selkoe DJ , et al: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84.

Games D. , Adams D. , Alessandrini R. , Barbour R. , Berthelette P. , Blackwell C. , et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-527.

Shearman MS , Beher D. , Clarke EE , Lewis HD , Harrison T. , Hunt P. , et al: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity . Biochemistry 2000;39:8698-8704.

10.

Johnson-Wood K. , Lee M. , Motter R. , Hu K. , Gordon G. , Barbour R. , et al: Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 1997;94:1550-1555.

11.

Espeseth AS , Xu M. , Huang Q. , Coburn CA , Jones KLG , Ferrer M. , et al: Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. J Biol Chem 2005;280:17792-17797.

12.

Majercak J. , Ray WJ , Espeseth A. , Simon A. , Shi X-P. , Wolffe C. , et al: LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103:17967-17972.

Development of Homogeneous 384-Well High-Throughput Screening Assays for Aβ1-40 and Aβ1-42 Using AlphaScreen™ Technology

Abstract

Keywords

References